Drug Trial Radar · NCT07896109
A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
121
Planned (sponsor's estimate)
Start
Oct 22, 2026
Primary completion
Jul 26, 2028
Study completion Jul 26, 2028
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Oct 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 25 years, up to 69 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to determine if the study medicine NNC9836-0001 is safe and tolerable in healthy participants with overweight or obesity or who have type 2 diabetes (T2D). Participants will either get the study medicine NNC9836-0001 or placebo. Which treatment participants get is decided by chance. NNC9836-0001 is a new medicine aimed to treat type 2 diabetes.
Conditions
- Diabetes Mellitus, Type 2
Interventions
NNC9836-0001Drug
NNC9836-0001 will be administered subcutaneously.
Placebo (NaCl)Drug
Placebo (NaCl) will be administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Single ascending dose (SAD): Number of Treatment emergent adverse events (TEAEs)Time frame: From dosing (day 1) until week 26
- Multiple ascending dose (MAD): Number of TEAEsTime frame: From dosing (day 1) to week 34
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Profil Institut für Stoffwechselforschung GmbH
Neuss, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.